Insulin receptor substrate 2 gene Gly1057Asp polymorphism is a risk factor for nonalcoholic fatty liver disease

• Published in: Laboratory medicine 2024-03, Vol.55 (2), p.215-219
• Main Authors: Nouri, Shadi, Mahmoudi, Touraj, Hojjati, Farzaneh, Najafabadi, Zeinab Nourmohammadi, Shafiee, Radmehr, Sayedsalehi, Shiva, Dehghanitafti, Atefeh, Ardalani, Abbas, Kohansal, Kiarash, Rezamand, Gholamreza, Asadi, Asadollah, Nobakht, Hossein, Dabiri, Reza, Farahani, Hamid, Tabaeian, Seidamir Pasha, Zali, Mohammad Reza
• Format: Article
• Language: English
• Subjects: Case-Control Studies; Genetic Predisposition to Disease; Genotype; Humans; Insulin Receptor Substrate Proteins - genetics; Insulin Receptor Substrate Proteins - metabolism; Non-alcoholic Fatty Liver Disease - genetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide - genetics; Risk Factors
• ISSN: 0007-5027; 1943-7730
• DOI: 10.1093/labmed/lmad066

Abstract Objective Nonalcoholic fatty liver disease (NAFLD), which is an emerging global chronic liver disease, has a close association with insulin resistance. We aimed to determine whether the Gly1057Asp (rs1805097) polymorphism of the insulin receptor substrate 2 (IRS2) gene is associated with NAFLD. Methods Using the polymerase chain reaction-restriction fragment length polymorphism method, 135 patients with biopsy-proven NAFLD and 135 controls underwent IRS2 genotype analysis. Results Genotype and allele distributions of the IRS2 gene Gly1057Asp variant conformed to the Hardy-Weinberg equilibrium in both the case and control groups (P > .05). The Asp/Asp genotype of IRS2 gene Gly1057Asp polymorphism compared with Gly/Gly genotype was associated with a 2.1-fold increased risk for NAFLD after adjustment for confounding factors (P = .029; odds ratio = 2.10, 95% CI = 1.23-3.97). Conclusion Our findings revealed for the first time that the Gly1057Asp Asp/Asp genotype of the IRS2 gene is a marker of increased NAFLD susceptibility; however, studies in other populations are required to confirm the results.